Stock Futures Plunge Sharply as Oil Prices Surge
Stock futures have moved sharply lower ahead of the open as a dramatic surge in oil prices tied to the escalating conflict involving Iran ripples through financial markets. Crude prices jumped above $100 per barrel and briefly approached roughly $120, the highest levels since 2022, after attacks on energy infrastructure and disruptions to shipping routes heightened fears of a global supply shock. The possibility that tanker traffic through the Strait of Hormuz could remain disrupted has forced traders to rapidly price in a geopolitical risk premium across energy markets.Equity markets reacted negatively to the sudden energy shock and indices fell across Asia and Europe as investors weighed the inflationary implications of higher fuel costs and the risk that the conflict could drag on. Some markets experienced particularly severe declines, with Asian stocks sliding sharply and South Korea's Kospi briefly halting trading after a steep drop, highlighting the speed of the risk-off move.Energy prices feed directly into transportation, manufacturing, and consumer costs, meaning a sustained spike in crude could push inflation expectations higher again and complicate central bank policy. At the same time, economic data released late last week signaled some cooling in the labor market, raising fears of a stagflationary environment where growth slows while price pressures rise.In pre-market trading, S&P 500 futures fell 1.13%, Nasdaq futures fell 1.22% and Dow futures fell 1.26%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Hims & Hersup 50% after entering into an agreement with Novo Nordiskthat will bring Ozempic injections and Wegovy pills and injections to the platform later this monthXenon Pharmaceuticalsup 48% after announcing its X-TOLE2 study of azetukalner in focal onset seizures met its primary endpointDianthusup 24% after reporting an early GO decision based on an interim responder analysis in the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy, CIDPLive Nationup 5% after Bloombergthe company is close to settling a federal antitrust lawsuit in a deal that would avoid the sale of its Ticketmaster unitApplied Optoelectronicsup 3% after announcing it received its first volume order for its 1.6T data center transceivers from one of its long-term major hyperscale customers to boost its network bandwidth for AI workloadUP AFTER EARNINGS -Heritage Insuranceup 6%DOWN AFTER EARNINGS -Beta Technologiesdown 3%LOWER -Jefferies Financialdown 3% after Morgan Stanley downgraded the stock to Equal Weight with a price target of $49, down from $78Lamb Westondown 1% after Starboard Value built a stake in the company and has been pushing to company to accelerate improvements and cost cuttingStarbucksdown 1% after Wolfe Research downgraded shares to Peer Perform after assuming coverage of the name
Trade with 70% Backtested Accuracy
Analyst Views on HIMS
About HIMS
About the author

- Executive Sell-off Plan: Hims & Hers CFO Oluyemi Okupe plans to sell up to 240,560 shares valued at approximately $4.89 million, which may raise concerns about the company's future confidence among investors.
- Stock Performance Volatility: Despite HIMS stock rising over 6% on Monday before the insider sale announcement, it fell 1% in premarket trading after the disclosure, indicating investor sensitivity to insider selling.
- New Product Launch: Hims recently launched a lineup of Novo Nordisk GLP-1 therapies, including FDA-approved Wegovy injections and various pill formulations, aimed at expanding its weight-loss platform, although the insider sale could impact market acceptance of these new products.
- Market Sentiment Deterioration: According to Stocktwits, retail sentiment for HIMS is bearish with extremely low message volume, reflecting investor unease about the company's future, particularly in light of the executive sell-off.

Stock Sale Announcement: Oluyeemi Okupé intends to sell 240.56K shares of Hims & Hers Health (HIMS.U.S) on April 6, with a total market value of approximately $4.89 million.
Reduction in Shareholding: Okupé has reduced his shareholding in Hims & Hers Health by 36,274 shares since January 5, 2026, with a total value of around $1.01 million.
- Market Volatility: Hims & Hers stock has exhibited significant volatility in recent months, reflecting market uncertainty regarding its future performance, which could impact investor confidence and capital inflows.
- Price Fluctuation: As of the afternoon of March 30, 2026, Hims & Hers stock was priced at $3.45, indicating instability in the market that may increase investment risks in the short term.
- Investor Attention: Due to the high volatility of the stock, investors may need to reassess their investment strategies to cope with potential price swings and market risks, thereby affecting the overall performance of their portfolios.
- Market Sentiment: The volatility of Hims & Hers stock may trigger changes in market sentiment, leading investors to develop varying perspectives on the company's future prospects, which could influence its market performance.
- Market Volatility: Hims & Hers (NYSE: HIMS) has recently emerged as one of the most volatile stocks in the market, reflecting investor uncertainty about its future performance, which could impact its short-term stock price.
- Lack of Investment Recommendations: The Motley Fool Stock Advisor analyst team has indicated that Hims & Hers is not among the current top 10 recommended stocks, suggesting a cautious market sentiment regarding its growth potential, which may lead investors to reassess its investment value.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which yielded returns of 515,294% and 1,077,442% respectively, Hims & Hers has not demonstrated similar appeal, indicating a lack of confidence in the stock.
- Investor Community Engagement: The Motley Fool encourages investors to join its community to share insights, and while Hims & Hers has not made the recommendation list, it still maintains a degree of attention among investors, potentially influencing future market dynamics.
- Legal Investigation Launched: The Schall Law Firm is investigating Hims & Hers Health for potential securities law violations, focusing on whether the company made false or misleading statements that could harm investors' interests.
- FDA Statement Impact: The FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, directly affecting Hims & Hers' market operations and potentially leading to stricter regulations.
- Increased Litigation Risk: Hims & Hers is also facing a lawsuit from Novo Nordisk seeking to bar the sale of compounded weight loss drugs, which will further escalate the company's legal risks and could impact its market share.
- Significant Stock Decline: Following these developments, Hims & Hers' shares fell by over 17.8% during afternoon trading on February 9, 2026, reflecting market concerns about the company's future prospects and potentially undermining investor confidence.
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.









